Table 1.
Main characteristics of the eligible studies.
| First author | Year | Country | Age, Median (range) | Cancer type | Stage range | MicroRNA | Sample size | Follow-up, Median (range) | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| Robaina, M.C.16 | 2016 | Brazil | 7.4 (2–18) | BL | I–IV | miR-17 | 39 | 38.5 (1–69) | OS |
| Ren, C.17 | 2016 | China | NA | GC | I–IV | miR-92a | 180 | 85.2 (79.2–97.2) | OS |
| Li, X.G.18 | 2016 | China | 43 (13–72) | GBM | I–IV | miR-17 | 108 | NA | OS |
| Chen, Y.J.19 | 2015 | China | NA | GC | I–III | miR-18a | 90 | NA | OS |
| Xi, Y.F.20 | 2015 | China | 18 (3–73) | T-LBL | I–IV | miR-17, miR-19 | 57 | NA (1–156) | OS |
| Su, X.P.21 | 2015 | China | NA | HCC | I–IV | miR-92a | 90 | NA | OS |
| Li, J.22 | 2015 | China | 58.7 (NA)* 56.6 (NA)** | CRC | II–III | miR-17-3p | 175 | 36 (33.0–38.1)* 32 (27.5–35.0)** | DFS |
| Hao, M.23 | 2015 | China | 57.5 (33–83) | MM | I–III | miR-19a | 108 | 13.5 (NA) | OS/DFS |
| Ge, Y.Z.24 | 2015 | China | 49.5 (42–62) | RCC | I–IV | miR-19a | 58 | 63.4 (31.5–86.1) | RFS |
| Guo, Y.H.25 | 2015 | China | NA | HCC | I–IV | miR-19 | 51 | NA | OS |
| Xu, X.L.26 | 2014 | China | 63 (45–81) | ESCC | I–IV | miR-17/miR-18a/miR-19a | 105 | 34.5 (0.89–52.0) | OS/PFS |
| Wu, C.H.27 | 2014 | China | NA | NSCLC | I–III | miR-19b | 155 | 29.0 (23.0–35.0) | OS |
| Su, Z.X.28 | 2014 | China | 69.0 (NA) | GC | T1–T4 | miR-18a | 82 | 49.8 (NA) | DFS/CSS |
| Lin, H.M.29 | 2014 | Australia | 68 (46–87) | PCa | NA | miR-20a | 97 | 12 (3–62) | OS |
| Fang, L.30 | 2014 | China | 59 (NA) | CRC | I–IV | miR-17-5p | 376 | NA | OS |
| Zhang, J.X.31 | 2013 | China | 65 (NA) | CC | II | miR-20a-5p | 735 | 66 (50–86) | DFS |
| Zhou, T.32 | 2013 | China | NA | CRC | I–IV | miR-92a | 82 | NA | OS |
| Sanfiorenzo, C.33 | 2013 | France | 65 (NA) | NSCLC | I–III | miR-20a-5p | 52 | NA | DFS |
| Mitani, Y.34 | 2013 | USA | NA | ACC | I–IV | miR-17/miR-20a/miR-92a | 30 | NA | OS |
| Liu, G.H.35 | 2013 | China | 57.09 (20–89) | CRC | I–IV | miR-92a | 166 | 36.4 (4–53) | OS |
| Lin, Q.36 | 2013 | China | 58 (NA) | NSCLC | I–III | miR-19a | 201 | 19 (NA) | OS |
| He, H.C.37 | 2013 | China | 59.80 (43- 86) | PCa | T2A–T4 | miR-19a | 104 | NA | RFS |
| Zheng, J.38 | 2012 | China | NA | HCC | I–IV | miR-17-5p | 96 | NA | OS |
| Chen, Q.39 | 2012 | China | NA | LC | III–IV | miR-17-5p | 221 | NA | OS |
| Yu, G.40 | 2012 | China | 63.0 (35–90) | CC | I–IV | miR-17/miR-18a/miR-19a/miR-19b | 48 | 59.5 (5–66) | OS |
| Wang, M.41 | 2012 | China | NA | GC | I–IV | miR-17-5p/miR-20a | 65 | 36 (NA) | OS |
| Nilsson, S.42 | 2012 | Sweden | 65 (NA) | BCa | I–III | miR-92a | 117 | 78 (NA) | RFS |
| Ma, Y.43 | 2012 | China | 69 (30–87) | CRC | I–IV | miR-17-5p | 425 | 45.60 (0.20–88.47)# 44.60 (0.17–86.53)## | OS |
| Chen, L.44 | 2012 | China | 60 (25–74) | HCC | I–IV | miR-17-5p | 120 | 20 (2–46) | OS/DFS |
| Valladares, A.M.45 | 2011 | Spain | 62.5 (45–76) | GIC | I–IV | miR-17 | 33 | 35 (0–90) | OS/PFS |
| Saito, M.46 | 2011 | USA Norway Japan | 63.6 (32–90) 64.4 (37–82) 59.6 (30–76) | NSCLC | I–III | miR-17 | 89/37/191 | NA | CSS/CSS/RFS |
| Marchini, S.47 | 2011 | Italy | 52 (21–82) | EOC | I | miR-20a | 89 | NA | OS/PFS |
| Liu, R.48 | 2011 | China | NA | PC | III–IV | miR-20a | 38 | NA | OS |
| Chen, Z.L.49 | 2010 | China | 60 (43–75) | ESCC | I–III | miR-92a | 65 | 74 (6–102) | OS |
| Yu, J.50 | 2010 | Japan | 65.5 (36–86) | PC | I–IV | miR-17-5p | 80 | NA | OS |
| Díaz, R.51 | 2008 | Spain | 69 (NA) | CC | I–IV | miR-17-5p | 110 | 68 (68–99) | OS/DFS |
NA, Not available; BL, Burkitt lym phoma; GC, Gastric cancer; T-LBL, T-cell lymphoblastic lymphoma; CRC, Colorectal cancer; RCC, Renal cell carcinoma; ESCC, Esophageal squamous cell carcinoma; MM, Multiple myeloma; NSCLC, Non-small cell lung cancer; LC, Lung cancer; CC, Colon cancer; GBM, Glioblastoma; ACC, Adenoid cystic carcinoma; BCa, Breast cancer; HCC, Hepatocellular carcinoma; GIC, Gastrointestinal cancer; EOC, Epithelial ovarian cancer; PC, Pancreatic cancer; PCa, Prostate cancer; OS, Overall survival; DFS, Disease-free survival; PFS, Progression-free survival; RFS, Recurrence or relapse-free survival; CSS, Cancer specific survival; *Tianjin cohort; **Xiangya cohort; #RT–PCR cohort; ##ISH cohort.